Literature DB >> 30221767

Trials and tribulations of neoadjuvant therapy in pancreatic cancer.

M Del Chiaro1, K Søreide2.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 30221767     DOI： 10.1002/bjs.11003

Source DB:  PubMed          Journal:  Br J Surg        ISSN： 0007-1323            Impact factor:   6.939


× No keyword cloud information.
  4 in total

1.  Impact of Neoadjuvant Systemic Therapy on Pancreatic Fistula Rates Following Pancreatectomy: a Population-Based Propensity-Matched Analysis.

Authors:  Fadi S Dahdaleh; Samer A Naffouje; Mark H Hanna; George I Salti
Journal:  J Gastrointest Surg       Date:  2020-04-06       Impact factor: 3.452

2.  Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy.

Authors:  Thomas Hank; Marta Sandini; Cristina R Ferrone; Clifton Rodrigues; Maximilian Weniger; Motaz Qadan; Andrew L Warshaw; Keith D Lillemoe; Carlos Fernández-Del Castillo
Journal:  JAMA Surg       Date:  2019-10-01       Impact factor: 14.766

3.  Heterogeneity in neoadjuvant therapy for localized pancreatic cancer: a persisting radiant autonomy.

Authors:  Kjetil Søreide
Journal:  Hepatobiliary Surg Nutr       Date:  2021-04       Impact factor: 7.293

4.  Neoadjuvant and Adjuvant Therapy in Operable Pancreatic Cancer: Both Honey and Milk (but No Bread?).

Authors:  Kjetil Søreide
Journal:  Oncol Ther       Date:  2021-01-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.